Patentscope RSS feed

NASAL ADMINISTRATION OF DESMOPRESSIN (Wed, 16 Jun 1999)
A pharmaceutical composition for single, effective and consistent plasma level, nasal administration comprises an aqueous solution having a volume of from about 5 to about 75 $g(m)l and from about 0.2 to about 2.0 mg/ml of desmopressin acetate, a molarly corresponding amount of desmopressin or a pharmaceutically acceptable salt of desmopressin. The composition is useful for the management of urinary disorders such as diabetes insipidus, incontinence, and nocturnal enuresis.
>> Read More

NASAL ADMINISTRATION OF DESMOPRESSIN (Tue, 30 Mar 1999)

>> Read More

Nasal administration of desmopressin (Fri, 28 May 1999)
This single dose pharmaceutical composition for nasal administration comprises an aqueous solution having a volume of from 5 to 75 ��l and the solution containing from 0.1 to 2.0 mg/ml of desmopressin, desmopressin acetate and a pharmaceutically acceptable salt of desmopressin.
>> Read More

NASAL ADMINISTRATION OF DESMOPRESSIN (Wed, 24 Dec 1997)
A pharmaceutical composition for single, effective and consistent plasma level, nasal administration comprises an aqueous solution having a volume of from about 5 to about 75 νl and from about 0.2 to about 2.0 mg/ml of desmopressin acetate, a molarly corresponding amount of desmopressin or a pharmaceutically acceptable salt of desmopressin. The composition is useful for the management of urinary disorders such as diabetes insipidus, incontinence, and nocturnal enuresis.
>> Read More

Composition for the treatment of fistula (Thu, 25 Sep 2014)
A composition for use in the treatment of fistula, the composition comprising activated carbon.
>> Read More

Microparticles comprising GNRH made by PGSS (Thu, 11 Aug 2016)
A pharmaceutical formulation comprising a solid matrix of one or more biodegradable polymers, the solid matrix including a pharmaceutically active substance or a pharmaceutically acceptable salt thereof distributed homogeneously or substantially homogeneously within the matrix; wherein the pharmaceutically active substance is, for example, a gonadotropin releasing hormone (GnRH), a GnRH agonist or a GnRH antagonist.
>> Read More

Heptapeptiidanaloogid (Wed, 15 Dec 1999)

>> Read More

ANALOGOS HEPTAPEPTIDICOS DE OXITOCINA. (Fri, 16 Apr 2004)
LA PRESENTE INVENCION SE REFIERE A UNOS ANALOGOS DE HEPTAPEPTIDOS O ALGUNAS DE SUS SALES FARMACEUTICAMENTE ACEPTABLES Y QUE ESTAN CONSTITUIDAS POR UN GRUPO FUNCIONAL HEXAPEPTIDO (S) Y DE UN RADICAL (Z) BE - AMINOALCOHOL CON TERMINACION C UNIDA AL GRUPO FUNCIONAL HEXAPEPTIDO (S) POR UN ENLACE DE AMIDA. EL BE -AMINOALCOHOL (Z) ES - NR - CH (Q) - CH 2 OH. "Q" ES (CH 2 ) N - NH - A. "N" VALE DE 1 A 6. "A" ES H O - C (=NH) NH 2 . "R" ES CH 3 O C 2 H SUB, 5 . EN ESTA FORMULA (S), X ES UN ACIDO AL AMINADO AROMA TICO EN D, E Y ES UN ACIDO AL - AMINADO ALIFATICO, X E Y PRESENTAN UNA ACTIVIDAD ANTAGONISTA DEL OXITOCINA. ESTA INVENCION, QUE SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE SINTESIS DE ESTOS ANALOGOS, SE REFIERE ADEMAS A UNAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS ANALOGOS, LA SINTESIS DE DICHAS COMPOSICIONES Y UN PROCEDIMIENTO DE REGULACION DE LAS CONTRACCIONES UTERINAS.
>> Read More

Desmopressiini manustamine nina kaudu (Mon, 16 Aug 1999)

>> Read More

High drug load mesalazine sachet (Wed, 27 Oct 2004)

>> Read More

PROCEDIMIENTO PARA PREPARAR ISOSTEROS DE POLIPEPTIDOS INHIBI DORES DE RENINA. (Fri, 01 Apr 1983)
PROCEDIMIENTO PARA PREPARAR ISOSTEROS DE POLIPEPTIDOS INHIBIDORES DE RENINA. SE HACE REACCIONAR SUCESIVAMENTE RESIDUOS EN FORMA SIMPLE O COMO UNIDADES PRE-SINTETIZADAS DE DOS O MAS RESIDUOS. SE OBTIENE UN ANALOGO DE POLIPEPTIDO DE FORMULA X-Y-PRO-PHE ABZW DONDE PRO, PHE, Y HIS PUEDEN ESTAR EN FORMA SUSTITUIDA. X A HIDROGENO, UN GRUPO ACILO U OTRO GRUPO N-PROTECTOR; Y ES D- O L-HIS Y OTRO RESIDUO AMINOACILO BASICO O AROMATICO D O L, O BIEN ESTA AUSENTE. EL POLIPEPTIDO SE MODIFICA POR SUSTITUCION ISOSTERICA EN UNO O AMBOS DE LOS ENLACES PRO-PHE O PHE-HIS.
>> Read More

PROCEDIMIENTO PARA PREPARAR ISOSTEROS DE POLIPEPTIDOS INHIBI DORES DE RENINA. (Fri, 01 Apr 1983)

>> Read More

DIAZACYCLOALKANES AS OXYTOCIN AGONISTS (Wed, 15 Sep 2004)
Compounds according to general formula (1), wherein G1 is NR5R6 or a fused polycyclic group are novel. They are selective and potent oxytocin agonists. Pharmaceutical compositions of such compounds are useful in the treatment of, inter alia, erectile dysfunction.
>> Read More

DESMOPRESINA DE ALTA PUREZA PRODUCIDA EN GRANDES LOTES SIMPLES (Mon, 11 Jan 1999)
La presente invención se refiere a un procedimiento para la manufactura de desmopresina de alta pureza producida en lotes simples de tamaño considerable y un método para tratar diabetes insipidus, hemofilia A, enfermedad de von Willebrand, nocturia, incontinencia y enuresis, con la desmopresina de alta pureza producida por medio del mismo.
>> Read More

SYNTHESIS OF CYCLIC PEPTIDES (Wed, 08 May 1996)
A process for preparing and purifying cyclic peptides having disulfide moieties in a single processing operation which simplifies synthesis and reduces production costs, yet produces high yields of pure peptide obtained by isolating the desired cyclic compound through direct ion exchange chromatography as an integral part of the single process. The improved process is particularly useful for the preparation of vasopressin and oxytocin and their respective derivatives and analogs.
>> Read More

STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES (Wed, 15 Jan 1997)
A solid pharmaceutical composition for oral administration of small and medium size peptides, particularly vasopressin, oxytocin, and their analogues, comprises said peptide, an enteric coat and a pharmaceutically acceptable carrier containing a buffering agent buffering at a pH of from 2 to 6, preferably at about pH 5. A method of manufacture of single doses of said peptide comprises mixing of the ingredients, forming the resulting mixture into spheres smaller than 2 mm, coating the spheres with an enteric coat which is readily soluble in gastric juice of pH 5.0 or higher but not at substantially lower pH, and filling the coated spheres in capsules or incorporating them into tablets, degradable in the stomach. Also disclosed is a method for oral administration to a patient of said single dose.
>> Read More

BIOLOGICALLY ACTIVE VASOPRESSIN ANALOGUES (Wed, 03 Apr 1996)
Vasopressin analogues of formula (I) wherein X is (S)-2-amino-2-methyl-butanoic acid (C$g(a)MeAbu) or Valine (Val), Y is Thienylalanine (Thi) or Methionine (Met), Z is D-Phenylalanine (D-Phe) or D-Thienylalanine (Thi) or D-Tyrosine (D-Tyr), are disclosed. Pharmaceutical preparations comprising a vasopressin analogue of the invention as active ingredient are disclosed and exemplified by oral preparations, nasal preparations, and intravenous preparations. The vasopressin analogues of the invention are intended for use as a medicament, specially an antidiuretic agent. The antidiuretic agent is preferably used for the treatment of diabetes insipidus or enuresis.
>> Read More

DIAZACYCLOALKANES AS OXYTOCIN AGONISTS (Sun, 20 Jun 2004)

>> Read More

VASOTOCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM (Wed, 16 Sep 1987)

>> Read More

DIAZACYCLOALKANES AS OXYTOCIN AGONISTS (Wed, 29 Dec 2004)
selective and potent oxytocin agonists. Pharmaceutical compositions of such compounds are useful in the treatment of, inter alia^ erectile dysfunction.
>> Read More